Close Menu

NEW YORK (GenomeWeb) – Almac Diagnostic Services and precision oncology pharma TP Therapeutics said today that are collaborating to develop and commercialize a next-generation sequencing companion diagnostic for TP's repotrectinib, an investigational tyrosine kinase inhibitor targeting ROS1, NTRK1-3 and ALK gene fusions in advanced solid tumors.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.